Pyxis Oncology to Participate in Upcoming Investor Conferences

Q: Who from Pyxis Oncology (PYXS) will be speaking at the September 2026 investor conferences?

According to Pyxis Oncology, Tom Civik, Interim Chief Executive Officer and Director, will participate in fireside chats at all three September 2026 investor conferences, representing the company in discussions with institutional investors and other attendees.

Q: What is Pyxis Oncology’s lead candidate MICVO and what cancers is it targeting?

MICVO (micvotabart pelidotin) is Pyxis Oncology’s lead antibody-drug conjugate targeting extradomain-B of fibronectin in the tumor microenvironment. According to Pyxis Oncology, it is being evaluated in recurrent and metastatic head and neck squamous cell carcinoma and other solid tumors.

Q: What clinical trials are underway for MICVO by Pyxis Oncology (PYXS)?

According to Pyxis Oncology, MICVO is in a Phase 1 monotherapy trial in recurrent and metastatic head and neck squamous cell carcinoma and a Phase 1/2 study in combination with Merck’s KEYTRUDA in patients with recurrent and metastatic head and neck squamous cell carcinoma and other solid tumors.

Q: Does MICVO from Pyxis Oncology (PYXS) have FDA Fast Track Designation?

Yes. According to Pyxis Oncology, MICVO received Fast Track Designation from the U.S. Food and Drug Administration for adult patients with recurrent and metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and an anti-PD-(L)1 therapy.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Positive)

Rhea-AI Summary

Pyxis Oncology (Nasdaq: PYXS) announced that Interim CEO and Director Tom Civik will participate in fireside chats at three investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference in Boston on September 10, the Cantor Global Healthcare Conference in New York on September 11, and the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14.

Live webcasts and replays will be available on the Investor Relations section of the company’s website. Pyxis Oncology’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin and is being evaluated in Phase 1 and Phase 1/2 studies in recurrent and metastatic head and neck squamous cell carcinoma and other solid tumors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

09/01/2026 - 07:30 AM

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.

Wells Fargo 21^st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.
2026 Cantor Global Healthcare Conference in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.
H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026, at 9:30 a.m. ET.

Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.

Pyxis Oncology Contact
IR@pyxisoncology.com

FAQ

When will Pyxis Oncology (PYXS) present at the Wells Fargo 21st Annual Healthcare Conference 2026?

Pyxis Oncology will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 10:15 a.m. ET. According to Pyxis Oncology, the event will take place in Boston, Massachusetts, with a live webcast available on its Investor Relations website.

What are the dates and times of Pyxis Oncology (PYXS) presentations at the 2026 Cantor and H.C. Wainwright conferences?

Pyxis Oncology will present at the 2026 Cantor Global Healthcare Conference on Friday, September 11, 2026, at 10:55 a.m. ET and at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 9:30 a.m. ET, both in New York, according to Pyxis Oncology.

How can investors access the Pyxis Oncology (PYXS) webcasts and replays for the September 2026 conferences?

Investors can access live webcasts and replays of Pyxis Oncology’s September 2026 fireside chats through the Events & Presentations page in the Investor Relations section of its website. According to Pyxis Oncology, this online access covers all three scheduled conference appearances.

Who from Pyxis Oncology (PYXS) will be speaking at the September 2026 investor conferences?

According to Pyxis Oncology, Tom Civik, Interim Chief Executive Officer and Director, will participate in fireside chats at all three September 2026 investor conferences, representing the company in discussions with institutional investors and other attendees.

What is Pyxis Oncology’s lead candidate MICVO and what cancers is it targeting?

MICVO (micvotabart pelidotin) is Pyxis Oncology’s lead antibody-drug conjugate targeting extradomain-B of fibronectin in the tumor microenvironment. According to Pyxis Oncology, it is being evaluated in recurrent and metastatic head and neck squamous cell carcinoma and other solid tumors.

What clinical trials are underway for MICVO by Pyxis Oncology (PYXS)?

According to Pyxis Oncology, MICVO is in a Phase 1 monotherapy trial in recurrent and metastatic head and neck squamous cell carcinoma and a Phase 1/2 study in combination with Merck’s KEYTRUDA in patients with recurrent and metastatic head and neck squamous cell carcinoma and other solid tumors.

Does MICVO from Pyxis Oncology (PYXS) have FDA Fast Track Designation?

Yes. According to Pyxis Oncology, MICVO received Fast Track Designation from the U.S. Food and Drug Administration for adult patients with recurrent and metastatic head and neck squamous cell carcinoma whose disease has progressed after platinum-based chemotherapy and an anti-PD-(L)1 therapy.